Posted on March 4th, 2013 by Logan Lafferty
Bevacizumab therapy can provide significant but temporary clinical benefit in persons with recurrent glioblastoma, acknowledged Panos Z. Anastasiadis, PhD, chair of the Department of Cancer Biology at Mayo Clinic in Jacksonville, Florida, and colleagues in their report for PLOS One. The drug causes these brain tumors to shrink by depriving them of blood nutrients, but certain proteins help the cancer cells migrate to blood vessels in other parts of the brain in search of more nutrients.
Oncology Nurse Advisor by Delicia Honen Yard
Tags: bevacizumab therapy, blood nutrients, brain tumors, Cancer, cancer cells, Department of Cancer Biology, Dr. Panos Z. Anastasiadis, Glioblastoma, Mayo Clinic Jacksonville, Oncology Nurse Advisor, PLoS One, proteins, Research
You must be logged-in to the site to post a comment.